Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03903250 · ClinicalTrials.gov registry record · NA
Effects of A-GPC on Reaction Time and Cognitive Function
A NA study, sponsored by University of Mary Hardin-Baylor.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03903250: Completed NA study, sponsored by University of Mary Hardin-Baylor.
NCT03903250 is a NA study that has completed, run by University of Mary Hardin-Baylor. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03903250, a NA study, has completed, sponsored by University of Mary Hardin-Baylor.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a randomized, double blind, crossover design study which measures the effect of alpha-glycerylphosphorylcholine (A-GPC) on reaction time and cognitive function in non-resistance trained males and females. Participants will complete baseline testing and then be randomized into one of two crossover treatments. Participants will report to the lab for five consecutive days whilst only getting a maximum of five hours of sleep per night from Monday through Thursday night. Once testing is complete on Friday, participants will receive a one week washout period then return to complete the opposite treatment.
Primary Outcome
The primary purpose of this investigation is to determine the effectiveness of alpha-glycerylphosphorylcholine (A-GPC) on changes in reaction time in young, non-resistance trained males and females. This will be accomplished by observing changes in reaction time via the Makoto Arena. The Makoto Arena is an instrument that utilizes lights and noises to assess reaction time. Participants are required to hit the lights when they appear on the tower as fast as possible. Participants are instructed t
Interventions
- DIETARY_SUPPLEMENT A-GPC
- DIETARY_SUPPLEMENT Sugar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2020-09-18 |
| Phase | NA |
What the finished NCT03903250 record still lists
NCT03903250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which A-GPC is the first listed.
NCT03903250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03903250 about?
NCT03903250 is a clinical study titled "Effects of A-GPC on Reaction Time and Cognitive Function". This is a randomized, double blind, crossover design study which measures the effect of alpha-glycerylphosphorylcholine (A-GPC) on reaction time and cognitive function in non-resistance trained males and females. Participants will complete baseline testing and then be randomized into one of two cros...
What is the current status of trial NCT03903250?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2019-03-25. Estimated completion is 2020-09-18.
What interventions are being tested in trial NCT03903250?
The interventions under investigation include: A-GPC (DIETARY_SUPPLEMENT), Sugar (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03903250?
This trial is sponsored by University of Mary Hardin-Baylor, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03903250's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI